# RESAR Update Contracts and IT Centralization


SEMIANNUAL MEETING SSO MARCH 9 2022





#### **ENROLLED PATIENTS**


RESAR



As of Sept 1st 2022


51 (+6 since Nov 2021)

Centers enrolling






#### **ENROLLED PATIENTS**





#### **ENROLLED PATIENTS**

51 Active Sites



# CONTRACTS

PLEASE CONTACT marco.fiore@istitutotumori.mi.it TO BE PREPARED

## "RESAR Vocabulary"

	AKA	Description	Note
Framework Agreement	DTA	Data transfer Agreement between INT and RESAR sites	Legal backbone for TARPSWG studies. Presently 12 Institutions are partners
Emended Framework Agreement		Will include centralization of data in the online Platform	Presently under consideration of 12 partners, then will be open to other centers
Study	Project	A single analysis run within RESAR (usually a subgroup analysis)	Example: Complexity Score, BISARC, etc.
Five Studies	5 studies	BISARC, Pattern of Care, Benchmarks, Response to Neoadjuvant, ResAntiPath	Regulated out of centralization process; already ongoing; closed to opt in
Accession Form	Appendix 1	To be signed by other sites to join the Emended Framework Agreement	
DUF	Appendix 2	Data Usage Form to regulate single studies within the Framework Agreement	For every single study a new DUF need to be signed
RESAR Platform	EXTRA	Online data entry website for centralization of RESAR	Presently tested for acquisition of retrospective data; will be used as prospective eCRF

#### **ONGOING CONTRACTS Activities**



5-studies: BISARC, Pattern of Care, Response to Neoadjuvant, ResAntiPath, Benchmarks

PRESENTLY ONGOING

1294 pts, 22 centers

Dataset will be sent to

Mark Fairweather

for analysis next week

PRESENTLY ONGOING

3 sites signed

3 sites pending

5-studies DUF for partner Sites

PLANNED BETWEEN JAN - MAR 2023

Sites will centralize 5studies data as as soon as they will sign DUF No modification to contracts will be possible

Complexity Score Study

Framework Agreement
Emendament
(centralization)

5-studies DUF for non partner Sites

Accession to Framework Agreement for Sites not involved in 5-studies

EMENDAMENT DRAFT CIRCULATED TO 12 PARTNER SITES

Waiting for comments from:

Toronto, Birmingham, Boston, IEO, Baltimora, John Hopkins, Roswell Park, Fox Chase Cancer Center

Deadline Monday Nov 28th for comments by Legal Offices

Deadline Dec 15th for signatures

Accession Document to Emended Framework Agreemet + DUF

PLANNED BETWEEN APR - JUL 2023

Sites will centralize existing data as soon as Framework Agreement is sign through Accession Form
No modification to contracts will be possible

## Status of Contract/Centralization of 44 Active Sites (TARRESIVE)



for more info: Daniela.Salvatore@istitutotumori.mi.it

**Alert Legend:** 

OK - ready

**Delay not related to Site** 

Delay related to Site Major Issue Pending

Institution	City	Activation Status	Framework Agreement n.1	Framenwork Agreement Process	Centralization Test	DUF 5-studies	PI contact
INT	Milano	Recruiting	<b>~</b>				
RMH	London	Recruiting					
Institut Curie	Paris	Recruiting					
Maria Sklodowska- Curie	Warsaw	Recruiting					
QEH	Birmingham	Recruiting	<b>~</b>				
Mount Sinai / Princess Margaret	Toronto	Recruiting	~				
Peter Mac	Melbourne	Recruiting	<b>~</b>				
LMU	Munich	Recruiting					
Samsung Medical Center	Seoul	Recruiting					
Ospedale Borgo Roma	Verona	Recruiting					
University of Montreal	Montreal	Recruiting					
NKI	Amsterdam	Recruiting					
Humanitas	Rozzano	Recruiting					
LUMC	Leiden	Recruiting					
Emory	Atlanta	Recruiting					
BWH/DFCI	Boston	Recruiting	<b>V</b>				
The Ottawa Hospital	Ottawa	Recruiting	<b>~</b>				
Candiolo Cancer Institute	Candiolo	Recruiting					
Institut Bergonié	Bordeaux	Recruiting					
Mayo Clinic	Jacksonville	Recruiting					
OSU	Columbus	Recruiting	<b>~</b>				
<b>Liverpool University</b>	Liverpool	Recruiting					

Institution	City	Activation Status	Framework Agreement n.1	Framenwork Agreement Process	Centralization Test	DUF 5-studies	PI contact
UC San Diego	San Diego	Recruiting					
National Cancer Center Hospital	Tokyo	Recruiting					
Tel-Aviv Sourasky	Tel-Aviv	Recruiting					
Peking University	Beijing	Recruiting					
Moffitt	Tampa	Recruiting					
Institute of Oncology Ljubljana	Ljubljana	Recruiting					
Royal Prince Alfred Hospital	Sydney	Recruiting					
Johns Hopkins University	Baltimore	Recruiting	<b>&gt;</b>				
IEO	Milano	Recruiting	<b>&gt;</b>				
MUMC	Mannheim	Recruiting					
Hospital Sant Pau	Barcelona	Recruiting					
Tata Memorial	Mumbai	Recruiting					
Campus Biomedico	Roma	Recruiting					
IOV	Padova	Recruiting					
A.C. Camargo Cancer Center	Sao Paulo	Recruiting					
Mary Bird Perkins	Baton Rouge	Recruiting					
Virgen de la Arrixaca	Murcia	Recruiting					
N.N. Blokhin	Moskow	Recruiting					
Roswell Park	Buffalo	Recruiting	<b>~</b>				
McGill University	Montreal	Recruiting					
Princess Alexandra Hospital	Brisbane	Recruiting					
Christian Medical College	Vellore	Recruiting					

## 11 Sites being activated

For more info: Daniela.Salvatore@istitutotumori.mi.it



Alert Legend:

OK - ready

**Delay not related to Site** 

**Delay related to Site** 

**Major Issue Pending** 

Institution	City	Activation Status	Framework Agreement n.1	Framenwork Agreement Process	Centralization Test	DUF 5-studies	PI contact
IPO	Porto	Approved, ready to recruit					
Saitama Medical Center	Saitama	Approved, ready to recruit					
Sylvester - Univ Miami	Miami	Approved, ready to recruit					
Patel Hospital	Karachi	Approved, ready to recruit					
Instituto de Oncologia Angel Roffo	Buenos Aires	Approved, ready to recruit					
Instituto Nacional de Cancerología	Bogotà	Approved, ready to recruit					
Tallaght Univesity Hospital	Dublin	Submitted to IRB, pending for decision					
Città della Salute e della Scienza	Turin	Submitted to IRB, pending for decision					
Royal Adelaide Hospital	Adelaide	Submitted to IRB, pending for decision					
CRO	Aviano	Submitted to IRB, pending for decision					
Aretaieio University Hospital	Athens	Submitted to IRB, pending for decision					

6 Sites: Ready to recruit

**5 Sites: Waiting for Local IRB Approval** 

## 31 Sites with Declaration of Interest (no further progress)



PLEASE FOR UPDATES: Marco.Fiore@istitutotumori.mi.it

City	Institution	Country	
Ann Arbor, MI	University of Michigan	USA	
Auckland	?	New Zealand	
Bern	Inselspital	Switzerland	
Boston	Massachusetts General Hospital	Massachusetts, USA	
Catania	Ospedale Garibaldi	Italy	
Coimbra	Instituto Português de Oncologia de Coimbra	Portugal	
Copenhagen	Rigshospital	Denmark	
Duarte	City of Hope National Medical Center	California, USA	
Gent	Ghent University Hospital	Belgium	
Göttingen	University Medical Center Göttingen	Germany	
Hong Kong	The Chinese University of Hong Kong / Prince of Wales Hospital	Hong Kong	
Houston	MD Anderson Cancer Center	Texas, USA	
Kansans City	The University of Kansas Health System	USA	
Kyiv	National Cancer Institute	Ukraine	
Leeds	St James's University Hospital	United Kingdom	
Leuven	UZ Leuven	The Netherlands	

City	Institution	Country
Maastricht	MUMC Maastricht University Medical Center	The Netherlands
Madrid	Hospital Gregorio Maranon	Spain
Mexico City	Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán	Mexico
Mexico City	Instituto National de Cancerologia	Mexico
Milwaukee	Aurora St. Luke's Medical Center	Wisconsin, USA
Muscat	Sultan Qaboos Comprehensive Cancer Care and Research Al Khoud	Oman
Napoli	Istituto Nazionale Tumori di Napoli - Fondazione Pascale	Italy
New Delhi	All India Institute of Medical Science AIIMS	India
New Haven	Yale New Haven Hospital	USA
Philadelphia	Fox Chase Cancer Center	Pennsylvania, USA
Portland, OR	Oregon Health and Science University	USA
Santiago	Instituto Oncológico Fundación Arturo López Pérez (FALP)	Chile
Sydney	Westmead Hospital	New South Wales, Australia
Taipei	National Taiwan University Hospital	Taiwan
Tel-Aviv	Sheba Medical Centre	Israel



#### CENTRALIZATION OF RESAR



ONLINE RESAR PLATFORM EXTRA

PRESENTLY ONGOING
BBS is contacting recruiting sites

26 sites still need to get in contact

Test for data centralization

**5-studies** DUF for partner Sites

Framework Agreement
Emendament
(centralization)

5-studies DUF for non partner Sites + Emended Framework Agreement

Accession to Framework
Agreement for Sites not
involved in 5-studies

Centralization of 12 partner sites


Centralization of 39 non-partner sites

PLANNED BETWEEN JAN - MAR 2023

Sites will centralize exiting data as soon as the Emendated Framework Agreement will be signed

PLANNED BETWEEN APR - JUL 2023

Sites will centralize exiting data as soon as they join the Emendated Framework Agreement



#### OPERATION \*

View patients

New patient

Import data

Researchers

#### ADMIN TOOLS ▼

Rules

Hospitals

Users

Fields

Studies

Quality Check

Summary

Insert patient

Back to Patient List

DEMOGRAPHICS				
Original PatientID  Insert orginal patientid to anonymize  Check ID	Sex			
Hospital			Country of origin	
		~		
Enter the age or calculate it by entering birth Date	and date of first biopsy or first surgery	Birth Date  gg/mm/aaaa		
Date of first biopsy or surgery			Age Please insert time at date of diagnosis or surgery	
gg/mm/aaaa				
Consent to participate Yes/No/NA			Date consented to participate  DD/MM/YYYY	
○ Yes ○ No ○ Not Applicable			gg/mm/aaaa	
ECOG performance status at time of consent  ○ 0 ○ 1 ○ 2 ○ 3 ○ 4				
Race				
White / Black / Asian / Latino / Other				
○ White ○ Black ○ Asian ○ Latino ○ Other				



## Ongoing RESAR projects: «the 5 studies»

Study	ID	Pls	Study time-frame	Participating Centers	Statistician
BISARC	R1905	S. Dumitra A. Gronchi	Jan 2017 – Jan 2020	21	TBD
Patterns of Care	R2005	H. Snow D. Gyorki	Jan 2017 — Jul 2022	29	Sophia Xie (Melbourne)
Response to Neoadjuvant	R2007	W. Van Houdt A. Gronchi S. Reijers	Jan 2017 – Oct 2020	19	TBD
ResAntiPath	R2006	M. Fiore A. Gronchi D. Strauss	Jan 2017 – Jan 2020	22	R. Miceli (Milan)
Benchmarks	R1906	A. Gronchi F. Tirotta M. Fiore	Jan 2017 – Dec 2021	24	TBD

#### 5-STUDIES DATA FLOW



5-studies: BISARC, Pattern of Care, Response to Neoadjuvant, ResAntiPath, Benchmarks

PRESENTLY ONGOING

3 sites signed3 sites pending

**5-studies** DUF for partner Sites

PLANNED BETWEEN JAN - MAR 2023

Sites will centralize 5-studies data as as soon as they will sign DUF

No modification to contracts will be possible

Complexity Score Study Framework Agreement
Emendament
(centralization)

5-studies DUF for non partner Sites

Accession Document to
Emendated Framework Agreemet
+ DUF

**DUF Signature** 

SITE WILL SEND EXCEL FILES TO INT (1 EXCEL FOR EACH STUDY)

INT WILL MERGE 5 FULL

DATASETS (1 DATASET FOR EACH

STUDY)

INT WILL SEND DATASET TO STUDY PI FOR ANALYSIS

R-2005

R-2007

R-1905

R-2006

R-1906

#### HOW Centralized RESAR WILL WORK



A PROSPECTIVE OBSERVATIONAL CONTROLLED STUDY

Action

Data Quality Check:

minimum mandatory

dataset for each patient

New retrospective study approved |

Specific Data
Quality Check on
dataset of interest

Upload of exiting data from all centers

Prospective data collection by eCRF

New prospective study approved

Randomization possible on the Platform

Regular monthly update from Excel – Filemaker local files

Action

Each center will be

offered to opt in for

participation in the study

Action

Local PIs will be able to check and

download their own patients in

Excel

#### FOR NEW CENTERS: HOW TO JOIN RESAR



#### OPEN TO ANY TARPSWG CENTER

DECLARATION OF INTEREST

Please contact: <a href="marco.fiore@istitutotumori.mi.it">marco.fiore@istitutotumori.mi.it</a> tarpswg@gmail.com

FOR DATA TRANSFER AGREEMENT

Contact

marco.fiore@istitutotumori.mi.it daniela.salvatore@istitutotumori.mi.it

DOCUMENTS: STUDY PROTOCOL, DATASET

LOCAL IRB
APPROVAL

JOIN EMENDED
FRAMEWORK AGREEMENT

CENTER ACTIVATION

FIND MATERIALS AND DOWNLOAD HERE:

tarpswg.org/resar-study-documentation

LOGIN FOR EXTRA
PLATFORM FOR ONLINE
DATA ENTRY WILL BE
RELEASED